Botulinum neurotoxin B (BoNT-B) mediates proteolytic cleavage of VAMP I/II (synaptobrevins I/II), which prevents vesicle-membrane fusion and blocks neurotransmitter release. In the present study, we investigated the effects of BoNT-B on neurotransmitter release in vivo from spinal primary afferent sensory fibers and the effects of this blockade on nociception. With intrathecally (IT) delivered BoNT-B in C57B/l6 mice, we characterized the effects of such block on the release of substance P (SP) from spinal afferent nociceptors (as measured by neurokinin-1 receptor, NK1-R, internalization), spinal neuronal activation (as indicated by spinal C-Fos expression) and nociceptive behavior after intraplantar (IPLT) formalin. In addition, we investig...
Despite the absence of synaptic contacts, cross-excitation of neurons in sensory ganglia during sign...
Botulinum neurotoxin type A1 (BoNT-A) reduces the peripheral peptide and cytokine upregulation in ra...
The mechanisms underlying the analgesic effects of botulinum toxin serotype A (BoNT-A) are not well ...
Botulinum neurotoxin B (BoNT-B) mediates proteolytic cleavage of VAMP I/II (synaptobrevins I/II) in ...
Increasing evidence suggests that botulinum neurotoxins (BoNTs) delivered into the skin and muscle i...
This study was presented in part as a poster at the meeting of the 3rd WIP Congress in Barcelona, Sp...
Recent work has shown that Botulinum toxins (BoNT) are taken up and transported in sensory nerve to ...
The antinociceptive action of botulinum toxin type A (BoNT/A) has been demonstrated in behavioral an...
Current evidence suggests that botulinum neurotoxins (BoNTs) A1 and B1, given locally into periphera...
Neurotoxins affecting neuroexocytosis can represent an innovative pharmacological approach to the in...
Current evidence suggests that botulinum neurotoxins (BoNTs) A1 and B1, given locally into periphera...
Peripheral nerve injury leads to sensory ganglion hyperexcitation, which increases neurotransmitter ...
In recent years a growing debate is about whether botulinum neurotoxins are retrogradely transported...
Despite the absence of synaptic contacts, cross-excitation of neurons in sensory ganglia during sign...
Chronic pain is a widespread debilitating condition affecting millions of people worldwide. Although...
Despite the absence of synaptic contacts, cross-excitation of neurons in sensory ganglia during sign...
Botulinum neurotoxin type A1 (BoNT-A) reduces the peripheral peptide and cytokine upregulation in ra...
The mechanisms underlying the analgesic effects of botulinum toxin serotype A (BoNT-A) are not well ...
Botulinum neurotoxin B (BoNT-B) mediates proteolytic cleavage of VAMP I/II (synaptobrevins I/II) in ...
Increasing evidence suggests that botulinum neurotoxins (BoNTs) delivered into the skin and muscle i...
This study was presented in part as a poster at the meeting of the 3rd WIP Congress in Barcelona, Sp...
Recent work has shown that Botulinum toxins (BoNT) are taken up and transported in sensory nerve to ...
The antinociceptive action of botulinum toxin type A (BoNT/A) has been demonstrated in behavioral an...
Current evidence suggests that botulinum neurotoxins (BoNTs) A1 and B1, given locally into periphera...
Neurotoxins affecting neuroexocytosis can represent an innovative pharmacological approach to the in...
Current evidence suggests that botulinum neurotoxins (BoNTs) A1 and B1, given locally into periphera...
Peripheral nerve injury leads to sensory ganglion hyperexcitation, which increases neurotransmitter ...
In recent years a growing debate is about whether botulinum neurotoxins are retrogradely transported...
Despite the absence of synaptic contacts, cross-excitation of neurons in sensory ganglia during sign...
Chronic pain is a widespread debilitating condition affecting millions of people worldwide. Although...
Despite the absence of synaptic contacts, cross-excitation of neurons in sensory ganglia during sign...
Botulinum neurotoxin type A1 (BoNT-A) reduces the peripheral peptide and cytokine upregulation in ra...
The mechanisms underlying the analgesic effects of botulinum toxin serotype A (BoNT-A) are not well ...